GUCY2C/Guanylyl cyclase C, His, Canine

GUCY2C/Guanylyl cyclase C, His, Canine

Guanylyl cyclase C (GUCY2C) has canonical centrality in defense of key intestinal homeostatic mechanisms, encompassing fluid and electrolyte balance, epithelial dynamics, antitumorigenesis, and intestinal barrier function. GUCY2C may represent a new target for anti-obesity pharmacotherapy.
Z03917
¥72,138.00

Ask us a question
Product Introduction
Species Canine
Protein Construction
GUCY2C/Guanylyl cyclase C (Tyr21-Gln430)
Accession # F1PAG3		 His
N-term C-term
Purity > 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 47.6 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 75-80 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from a 0.22 μm filtered solution in PBS, pH 7.4 .
Reconstitution It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH2O more than 100 μg/ml.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Background
Target Background Guanylyl cyclase C (GUCY2C) has canonical centrality in defense of key intestinal homeostatic mechanisms, encompassing fluid and electrolyte balance, epithelial dynamics, antitumorigenesis, and intestinal barrier function. GUCY2C may represent a new target for anti-obesity pharmacotherapy.
Synonyms Guanylyl cyclase C; GC-C; STAR; GUCY2C; GUC2C; STA receptor; DIAR6; EC 4.6.1; GCC; GUC2CEC 4.6.1.2; MUCIL

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.